# Polygenic Prediction of Type 2 Diabetes in Africa

*Diabetes Care 2022;45:717–723 | https://doi.org/10.2337/dc21-0365*

Tinashe Chikowore,[1,2] Kenneth Ekoru,[3] Marijana Vujkovi,[4] Dipender Gill,[5,6] Fraser Pirie,[7] Elizabeth Young,[8] Manjinder S. Sandhu,[9] Mark McCarthy,[10] Charles Rotimi,[3] Adebowale Adeyemo,[3] Ayesha Motala,[7] and Segun Fatumo[11,12]

## OBJECTIVE

Polygenic prediction of type 2 diabetes (T2D) in continental Africans is adversely affected by the limited number of genome-wide association studies (GWAS) of T2D from Africa and the poor transferability of European-derived polygenic risk scores (PRSs) in diverse ethnicities. We set out to evaluate if African American, European, or multiethnic-derived PRSs would improve polygenic prediction in continental Africans.

## RESEARCH DESIGN AND METHODS

Using the PRSice software, ethnic-specific PRSs were computed with weights from the T2D GWAS multiancestry meta-analysis of 228,499 case and 1,178,783 control subjects. The South African Zulu study ($n$ = 1,602 case and 981 control subjects) was used as the target data set. Validation and assessment of the best predictive PRS association with age at diagnosis were conducted in the Africa America Diabetes Mellitus (AADM) study ($n$ = 2,148 case and 2,161 control subjects).

## RESULTS

The discriminatory ability of the African American and multiethnic PRSs was similar. However, the African American–derived PRS was more transferable in all the countries represented in the AADM cohort and predictive of T2D in the country combined analysis compared with the European and multiethnic-derived scores. Notably, participants in the 10th decile of this PRS had a 3.63-fold greater risk (odds ratio 3.63; 95% CI 2.19–4.03; $P$ = $2.79 \times 10^{-17}$) per risk allele of developing diabetes and were diagnosed 2.6 years earlier than those in the first decile.

## CONCLUSIONS

African American–derived PRS enhances polygenic prediction of T2D in continental Africans. Improved representation of non-European populations (including Africans) in GWAS promises to provide better tools for precision medicine interventions in T2D.

[1]MRC/Wits Developmental Pathways for Health Research Unit, Department of Pediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
[2]Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
[3]Center for Research on Genomics and Global Health, National Institute of Health, Bethesda, MD
[4]Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
[5]Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, U.K.
[6]Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, London, U.K.
[7]Department of Diabetes and Endocrinology, University of KwaZulu-Natal, Durban, South Africa
[8]Omnigen Biodata Ltd, Cambridge, U.K.
[9]Department of Epidemiology and Biostatistics, Imperial College, London, U.K.
[10]Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, U.K.
[11]London School of Hygiene and Tropical Medicine, London, U.K.
[12]The African Computational Genomics Research Group, MRC/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine (Uganda Research Unit), Entebbe, Uganda

Corresponding author: Segun Fatumo, segun.fatumo@lshtm.ac.uk, or Tinashe Chikowore, tinashe.chikowore@wits.ac.za

The global prevalence of diabetes mellitus in 2019 was estimated to be 463 million individuals (1), of whom 19.4 million were from Africa. Type 2 diabetes (T2D) is the most common form of diabetes in Africa, accounting for 90% of cases. African countries are adversely affected by limited resources to manage this burden. Nonetheless, it is projected that by 2045 Africa will experience the largest increase in diabetes prevalence in the world, at 143% (1,2). In addition, the highest proportion (59.7%) of undiagnosed people living with diabetes in the world reside in Africa

(1). Therefore, urgent strategies and resources for improving screening and early identification interventions are required to help curb this pandemic in Africa.

T2D is a multifactorial disease that is hypothesized to be increasing in prevalence due to the interaction of genetic and environmental factors (3). Although the genetic factors are stable over time, the surge in diabetes prevalence over the past decades is thought to have been caused by urbanization and the adoption of westernized lifestyles characterized by consumption of energy-dense foods and physical inactivity (3,4). However, diabetes has been noted to be preventable, and its onset was delayed for 15 years by diet and exercise interventions in the Diabetes Prevention Program (5). Because diet and exercise strategies are readily accessible and relatively low cost, coupling these lifestyle interventions with approaches that identify people earlier who are more susceptible to developing diabetes might effectively lower the diabetes burden. The use of polygenic risk scores (PRSs) for early identification of people who are more genetically susceptible to developing T2D is such an approach (6). Recent studies conducted in Europeans have indicated that individuals in the 10th decile have a 5.21-fold higher risk (odds ratio [OR] 5.21; 95% CI 4.94–5.49) of developing diabetes compared with those in the first decile (7). However, evidence exists of the poor transferability of European-derived polygenic scores in diverse populations. For example, Martin et al. (8) reported that European PRSs had a 4.9-fold reduced predictive value in African Americans across 17 traits. There is now a concern that African ancestry and other similarly under-studied population groups may not benefit from the clinical translation efforts of these PRSs, thereby exacerbating existing health disparities (8,9).

Large multiethnic cohorts such as the Million Veteran Program improve the representation of African Americans in genome-wide association studies (GWAS) and offer a promise of enhanced polygenic prediction in this group (10). However, the representation of continental Africans in GWAS is still very low, both in the number of studies and the total number of study participants. For example, T2D GWAS with >1 million European

participants are being reported, while the sample sizes of continental Africans remain under 10,000 (7,11). Therefore, continental Africans face a much worse threat than do African Americans of under-representation in precision medicine efforts for T2D (9). It has been reported that multiethnic PRSs (compared with European-only PRSs) might enhance prediction in diverse populations (12,13). However, the predictive ability of the multiethnic-derived PRSs and that of African Americans who originated mainly from the Western part of Africa and have approximately an 80% Africa admixture is yet to be evaluated in continental Africans (12,13). We set up this study to assess the predictive ability of European-, African American–, and multiethnic-derived PRSs for T2D in continental Africans.

## RESEARCH DESIGN AND METHODS

### Study Participants

Black South African participants from the Durban Case-Control Study ($n$ = 1,602 case subjects) who were attending a diabetes clinic in the same location in Durban as the 981 control subjects from the cross-sectional Durban Diabetes Study were aggregated and collectively regarded as the South African Zulu study, as indicated elsewhere (11,14). These individuals were older than 18 years, not pregnant, and from urban black African communities in Durban, South Africa (14). The World Health Organization criteria were used to define T2D status. The validation-study participants were from the Africa America Diabetes Mellitus (AADM) study, which has been described in detail elsewhere (15–17). The 2,148 case subjects and 2,161 control subjects from this study were enrolled at university medical centers in Nigeria ($n$ = 1,325 case subjects and 1,363 control subjects), Ghana (449 cases and 435 controls) and Kenya (374 cases and 363controls) (17). In this study, diabetes was defined based on an oral glucose tolerance test or pharmacological treatment of diabetes (17). Written informed consent was completed by the study participants. The respective studies were approved by relevant ethics committees under the following references: Durban Case-Control Study, BF078/08; Durban Diabetes Study, BF030/12; and AADM, 14/WM/1061).

### Genotyping and Imputation

Participants in the South African Zulu study (Supplementary Table 1) were genotyped using the Illumina Multi-Ethnic Genotyping Array (Illumina, San Diego, CA). The Affymetrix Axiom PanAFR single nucleotide polymorphism (SNP) array (Thermo Fisher Scientific, Waltham, MA) or Illumina Multi-Ethnic Genotyping Array was used to genotype participants in the AADM study. Detailed quality control and imputation for these studies were performed using African whole genomes from the Uganda 2000 Genomes and the 1000 Genomes as reference panels, as has been described elsewhere (11,18). A minimum minor allele frequency threshold of 0.5% and imputation information score >0.4 was applied (11).

### Statistical Analysis

PRSice 2 software was used to implement the clumping and threshold approach for developing PRSs. After sensitivity analysis, a clumping distance of 500 kb and an $r^2$ of 0.5 were parameters used for computing PRSs. GWAS summary statistics from the multiancestry GWAS of T2D by Vujkovic et al. (7), comprising participants representative of Europeans, African Americans, Hispanics, and Asians, were used as the base (discovery), and genotype data from the South African Zulu study and AADM were used as the target data and validation data sets, respectively, as listed in Table 1.

In the discovery analysis, multiple PRSs were computed at $P$ value thresholds from 1 to $5 \times 10^{-8}$ of the base data set and linkage disequilibrium clumping was done using the target data set as the reference. The predictivity of these PRSs was then evaluated through linear models that adjusted for age, sex, and population stratification (five principal components). The $P$ values of these PRSs and the Nagelkerke $R^2$ were evaluated to assess transferability and predictability, respectively (Supplementary Figs. 2–4). The best predictive multiethnic, African American, and European PRSs were then validated in the AADM study, as shown in Table 1 and Supplementary Table 2.

During the validation stage, the best predictive PRSs were assessed for transferability and predictivity through the $P$ values and Nagelkerke $R^2$ in linear models implemented in PRSice, which corrected for age, sex, BMI, and population

**Table 1—Comparisons of the predictive ability of ethnically derived PRSs on T2D in continental Africans**

|  | Multiethnic | African American | European |
|---|---|---|---|
| Discovery data set (multiancestry meta-analysis) | | | |
|   Case subjects | 228,499 | 24,646 | 148,726 |
|   Control subjects | 1,178,783 | 31,446 | 965,732 |
| PRS development | | | |
|   Target data set (South African Zulu) | | | |
|     Case subjects | 1,602 | 1,602 | 1,602 |
|     Control subjects | 981 | 981 | 981 |
|   PRS parameters | | | |
|     $P$ for threshold | $3 \times 10^{-4}$ | $5 \times 10^{-8}$ | 0.0608 |
|     No. of SNPs | 41,815 | 65 | 405,572 |
|     Nagelkerke $R^2$, % | 0.69 | 1.11 | 0.69 |
|     $P$ value | $4.62 \times 10^{-6}$ | $3.90 \times 10^{-9}$ | $5.09 \times 10^{-6}$ |
|     OR (95% CI)* | 1.29 (1.16–1.43) | 1.58 (1.36–1.84) | 1.01 (1.00–1.01) |
|     $P$ value* | $3.52 \times 10^{-6}$ | $4.80 \times 10^{-9}$ | $9.54 \times 10^{-6}$ |
| Validation of PRS | | | |
|   Validation data set (AADM) | | | |
|     Case subjects | 2,148 | 2,148 | 2,148 |
|     Control subjects | 2,161 | 2,161 | 2,161 |
|   PRS parameters | | | |
|     $P$ for threshold | $3 \times 10^{-4}$ | $5 \times 10^{-8}$ | 0.0608 |
|     No. of SNPs | 41,553 | 65 | 1,408,065 |
|     Nagelkerke $R^2$ % | 2.62 | 2.92 | 0.13 |
|     $P$ value | $1.06 \times 10^{-21}$ | $9.38 \times 10^{-24}$ | $2.99 \times 10^{-2}$ |
|     OR (95% CI)* | 1.04 (1.03–1.05) | 1.57 (1.47–1.67) | 1.004 (1.03–1.05) |
|     $P$ value* | $1.41 \times 10^{-21}$ | $5.91 \times 10^{-23}$ | $3.16 \times 10^{-2}$ |

*Models adjusted for ancestry indicated by 5 principal components, age, sex, and BMI.

stratification (five principal components), as shown in Table 1. This was first done for the whole of the AADM study and then at the country level, as shown in Fig. 1B.

The best predictive PRS from the three discovery data sets was then used to assess its risk stratification and diagnostic utility. Logistic regression models for the PRS deciles as a predictor variable were computed while correcting for age, sex, BMI, and residual population, structure using principal components (five principal components). A shape plot was computed to show the differences in risk of the PRS deciles from the first decile, as shown in Fig. 1A. Finally, a linear regression model was used to evaluate whether the age at which patients are diagnosed with diabetes ($n = 1,031$) is affected by PRS in the AADM study.

## RESULTS

### Polygenic Score Development and Validation
From the linear models of the multiple PRSs generated using the PRSice software (Supplementary Figs. 2–4), the best predictive PRS from the data on Europeans, the multiethnic group, and African Americans was significant and had the highest variance as indicated by Nagelkerke $R^2$ values of 0.69% ($P = 5.09 \times 10^{-6}$), 0.69% ($P = 3.90 \times 10^{-9}$), and 1.11% ($P = 4.62 \times 10^{-6}$), respectively (Table 1). The best PRSs were validated in the AADM study and were noted to be all significant in a similar trend. The African American PRS had the highest predictability, indicated by a Nagelkerke $R^2$ of 2.92% ($9.38 \times 10^{-24}$) in the combined analysis of the countries, as reported in Table 1.

### PRS Stratification and Transferability in African Countries
The participants in the 10th decile of the African American–derived PRS had a more than threefold higher risk for developing T2D per risk allele, compared with those in the first decile in the AADM study (OR 3.63; 95% CI 2.19–4.03; $P = 2.79 \times 10^{-17}$) (Fig. 1A). On average, participants in the 10th decile of the African American PRS in the AADM study were diagnosed with T2D 2.6 years earlier ($\beta = -2.61$; $P = 0.046$) than participants in the first decile (Fig. 2B). The African American PRS was transferable in all countries compared with the multiethnic PRS that was not in Kenya. The PRS predictability (indicated by Nagelkerke $R^2$) varied greatly between the East Africa country of Kenya and two West Africa countries, Ghana and Nigeria, where predictability was much higher for both the African American and the multiethnic PRSs.

### Discriminatory Ability of the PRS
The model with the conventional risk factors of age, BMI, five principal components, and sex had an area under the curve (AUC) C-statistic of 67.9%, whereas that of the African American PRS, five PCs, age, BMI, and sex was 69.8% (Fig. 2), which was almost similar to the multiethnic PRS of multiethnic of 69.9%. Therefore, there was improved discriminatory ability by 1.9%, with the addition of the African American PRS to the conventional risk factors.

## CONCLUSIONS
We set out to assess the predictive value of T2D PRS in continental Africans. We compared the polygenic prediction of African American, European, and multiethnic PRSs for T2D in continental Africans. The PRS with the best prediction was derived from an African American restricted GWAS (7). Participants in the 10th decile of this PRS had a more than threefold increased risk of developing

**A**



**B**



**Figure 1**—*A*: Shape plot for the difference in odds ratio for T2D (adjusted for age, sex, BMI, and five principal components) in reference to the first decile for the African American PRS in the AADM study. *B*: Bar plots showing the transferability of the PRS in African countries represented in the AADM study.

T2D and were diagnosed 2.6 years earlier, on average, than those in the first decile.

Limited studies of candidate SNP PRS have been performed on data from continental Africans. Previously, we reported a genetic risk score with weights from Europeans that was associated with an OR of 1.21 (95% CI 1.02–1.43) for T2D in Black South Africans (19). This genetic risk score had an AUC of 0.665, together with conventional risk factors for T2D (19). However, this study was limited due to the small sample size ($n = 356$),

the availability of only genotyped SNPs, and the use of weights that were derived from European-only studies. In the present study, we have substantially expanded the sample size ($n = 2,383$), enhanced genome coverage by imputing to 1000 Genomes and local African Ancestry whole genomes (18), and used a multiethnic discovery data set GWAS that included 1.4 million individuals, including people of African American ancestry. We performed a country-level analysis that showed less variable predictability within regional countries in

West Africa (Ghana and Nigeria) and greater variability when comparing with other countries from other regions, such as Kenya in East Africa. This phenomenon is suggestive of the usefulness of regional PRSs in Africa. However, this will need to be validated by additional studies.

Nonetheless, polygenic predictions of European-derived PRSs in Europeans are still higher than that of the African Americans in continental Africans (7). Notably, participants in the top decile of a European-derived PRS have recently

**Figure 2**—*A*: Receiver operating curves for the African American–derived PRS and conventional risk factors for the prediction of T2D in the AADM study. Full model refers to age, sex, BMI, African American PRS, and 5PCs. *B*: Shape plot for the difference of age at diagnosis for T2D in the AADM study for the African American–derived PRS. 5PCs, five principal components.

been reported to have a greater than fivefold risk for developing T2D than those in the first decile in Europeans (7). In our study, failure to reach predictions denoted in Europeans might be because the African American–derived PRSs are from an admixed population group that is not representative of the genetic diversity and linkage disequilibrium patterns of continental Africans (13,20). In addition, vast improvements in sizes of the European cohorts that are now >1 million individuals is indicative of substantial power compared with African diabetes cohorts that are still below the 10,000 mark (21). More investments are required to increase the representation of continental Africans in GWAS of T2D.

Recently, it was reported that the multiancestry PRS outperforms the population-specific ones from Europeans and East Asians (22). However, this phenomenon is yet to be validated in continental Africans. Considering that 80% of GWAS have been done in Europeans, most multiancestry GWAS meta-analyses are biased toward this population group (8). Marquez-Luna et al. (12) combined the training and the target data set summary statistics to compute the PRS and then showed that the multiethnic PRSs improve prediction in diverse populations. However, this approach is not widely accepted, and more research is still required to validate if the multiethnic PRS outperforms the population-specific PRS for all the ancestries (23,24). In our study, the African American and multiethnic PRSs had similar discriminatory abilities. However, the African American PRS was slightly more predictive than the multiancestry PRS for the combined AADM study and, with improved representations of Africans, these predictions might increase in the future. In addition, the country-stratified analyses also indicated that the multiancestry PRS was not transferable to participants from Kenya. The failure to tag the causal variant due to differences in allele frequencies, linkage disequilibrium patterns, and heterogeneity of effect sizes is a potential reason for the limited predictivity of multiancestry meta-analysis of continental Africans, who have greater genetic diversity (25–27).

The utility of PRSs is an issue of paramount importance for clinical translation

(6). The African American PRS, though it was predictive for T2D in continental Africans, only improved the AUC of conventional risk factors by 1.9%, and when combined with principal components, its AUC was 69.8%, and that of the conventional risk factors was 67.9%. Similarly, in a Swedish T2D study, the European-derived PRS increased the AUC by 1%, compared with conventional risk factors (28). However, the use of AUC as a measure to evaluate the clinical utility of polygenic prediction is being debated, because AUC is regarded a less-sensitive metric (29). There are ongoing efforts to develop better metrics (30). Nonetheless, findings from this study that people with T2D and a high PRS are typically diagnosed with diabetes at an earlier age and have a 3.6-fold risk of developing diabetes are of clinical importance. They may be useful in the prevention and treatment of diabetes.

Our study was limited by the sparse number of T2D GWAS in continental Africans. Nonetheless, the African American–derived PRS improved disease classification in this population. The clumping and thresholding approach used to compute the genome-wide PRS did not account for environmental factors such as diet and exercise that might confound the predictive accuracy of these measures. The strengths of our study include validation of the African American PRS in the AADM study and that we used GWAS summary statistics of varied ethnicities from the same study, which minimized bias due to genotyping and GWAS designs.

In summary, an African American–derived PRS seems to be the best predictor of T2D in continental Africans compared with European and multiethnic PRSs. More studies are required to determine whether using continental African GWAS might further enhance these predictions and reach a similar accuracy as in Europeans. Although the PRS prediction of diabetes had low specificity and sensitivity, patient stratification by PRS may prove clinically useful.

**Author Contributions.** T.C. and S.F. conceptualized the study, performed the main analyses, and wrote the first draft. K.E. and A.A. performed the validation analysis. All the authors read and provided critical feedback on the manuscript. S.F. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

## References

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843
2. Ekoru K, Doumatey A, Bentley AR, et al. Type 2 diabetes complications and comorbidity in Sub-Saharan Africans. EClinicalMedicine 2019;16:30–41
3. Langenberg C, Lotta LA. Genomic insights into the causes of type 2 diabetes. Lancet 2018; 391:2463–2474
4. Hansen T. Type 2 diabetes mellitus–a multifactorial disease. Ann Univ Mariae Curie Sklodowska Med 2002;57:544–549
5. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3:866–875
6. McCarthy MI, Mahajan A. The value of genetic risk scores in precision medicine for diabetes. Expert Rev Precis Med Drug Dev 2018;3:279–281
7. Vujkovic M, Keaton JM, Lynch JA, et al.; HPAP Consortium; Regeneron Genetics Center; VA Million Veteran Program. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet 2020; 52:680–691
8. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet 2019;51:584–591
9. Doumatey AP, Ekoru K, Adeyemo A, Rotimi CN. Genetic basis of obesity and type 2 diabetes in Africans: impact on precision medicine. Curr Diab Rep 2019;19:105
10. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 2016;70:214–223
11. Chen J, Sun M, Adeyemo A, et al. Genome-wide association study of type 2 diabetes in Africa. Diabetologia 2019;62:1204–1211
12. Márquez-Luna C, Loh PR; South Asian Type 2 Diabetes (SAT2D) Consortium; SIGMA Type 2 Diabetes Consortium. Multiethnic polygenic risk scores improve risk prediction in diverse populations. Genet Epidemiol 2017;41:811–823
13. Zakharia F, Basu A, Absher D, et al. Characterizing the admixed African ancestry of African Americans. Genome Biol 2009;10:R141
14. Hird TR, Young EH, Pirie FJ, et al. Study profile: the Durban Diabetes Study (DDS): a platform for chronic disease research. Glob Health Epidemiol Genom 2016;1:e2
15. Rotimi CN, Chen G, Adeyemo AA, et al.; Africa America Diabetes Mellitus (AADM) Study. A genome-wide search for type 2 diabetes susceptibility genes in West Africans: the Africa America Diabetes Mellitus (AADM) Study [published correction appears in Diabetes 2004;53: 1404]. Diabetes 2004;53:838–841
16. Rotimi CN, Dunston GM, Berg K, et al. In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study. Ann Epidemiol 2001; 11:51–58
17. Adeyemo AA, Tekola-Ayele F, Doumatey AP, et al. Evaluation of genome wide association study associated type 2 diabetes susceptibility loci in Sub Saharan Africans. Front Genet 2015; 6:335
18. Gurdasani D, Carstensen T, Fatumo S, et al. Uganda genome resource enables insights into population history and genomic discovery in Africa. Cell 2019;179:984–1002.e36
19. Chikowore T, van Zyl T, Feskens EJ, Conradie KR. Predictive utility of a genetic risk score of common variants associated with type 2 diabetes in a black South African population. Diabetes Res Clin Pract 2016;122:1–8
20. Choudhury A, Aron S, Botigué LR, et al.; TrypanoGEN Research Group; H3Africa Consortium. High-depth African genomes inform human migration and health. Nature 2020;586:741–748

21. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018;50:1219–1224

22. Koyama S, Ito K, Terao C, et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat Genet 2020;52:1169–1177

23. Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc 2020;15:2759–2772

24. Babb de Villiers C, Kroese M, Moorthie S. Understanding polygenic models, their development and the potential application of polygenic scores in healthcare. J Med Genet 2020;7:725–732

25. Morris AP. Transethnic meta-analysis of genomewide association studies. Genet Epidemiol 2011;35:809–822

26. Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun 2019;10:3328

27. Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet 2016;17:392–406

28. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes. Worthless or valuable? Diabetes Care 2013;36:S120–S126

29. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928–935

30. Baker SG. Metrics for Evaluating Polygenic Risk Scores. JNCI Cancer Spectr 2020;5:pkaa106